title: Effect of Iranian Honey bee (Apis mellifera) Venom on Blood Glucose and Insulin in Diabetic Rats.
abstract: BACKGROUND
  Diabetes is an important disease. This disease is a metabolic disorder characterized by hyperglycemia resulting from perturbation in insulin secretion, insulin action or both. Honey bee venom contains a wide range of polypeptide agents. The principle components of bee venom are mellitin and phospholipase A(2). These components increase insulin secretion from the β-cells of pancreas. This study was conducted to show the hypoglycemic effect of honey bee venom on alloxan induced diabetic male rats.
  
  
  METHODS
  Eighteen adult male rats weighting 200±20 g were placed into 3 randomly groups: control, alloxan monohydrate-induced diabetic rat and treated group that received honey bee venom daily before their nutrition for four months. Forty eight hours after the last injection, blood was collected from their heart, serum was dissented and blood glucose, insulin, triglyceride and total cholesterol were determined.
  
  
  RESULTS
  Glucose serum, triglyceride and total cholesterol level in treated group in comparison with diabetic group was significantly decreased (P< 0.01). On the other hand, using bee venom causes increase in insulin serum in comparison with diabetic group (P< 0.05).
  
  
  CONCLUSIONS
  Honeybee venom (apitoxin) can be used as therapeutic option to lower blood glucose and lipids in diabetic rats.
authors: Department of Entomology, Islamic Azad University, Tehran Science and Research Branch, Iran.
authors: Seyyedeh Mahbubeh
authors: SM
authors: Mousavi
authors: Sohrab
authors: S
authors: Imani
authors: Saeid
authors: S
authors: Haghighi
authors: Seyyedeh Elaheh
authors: SE
authors: Mousavi
authors: Akbar
authors: A
authors: Karimi
keywords: Alloxan; Glucose; Honeybee Venom; Rat
references: Biosci Rep. 1984 Aug;4(8):665-71
references: 6388655
references: Gastroenterology. 1989 Dec;97(6):1498-505
references: 2583415
references: Evid Based Complement Alternat Med. 2005 Mar;2(1):79-84
references: 15841281
references: Eksp Klin Farmakol. 1992 Jan-Feb;55(1):42-4
references: 1305433
references: Endocrinology. 1987 May;120(5):1750-7
references: 3552622
references: J Biosci. 2004 Mar;29(1):81-91
references: 15286407
references: Cell Mol Life Sci. 2008 Oct;65(20):3196-217
references: 18597044
references: Eur J Biochem. 1976 Jan 15;61(2):369-76
references: 1248464
references: Agents Actions. 1989 Jun;27(3-4):425-7
references: 2552770
references: Int J Dev Neurosci. 2007 Jun;25(4):259-64
references: 17467222
references: J Korean Med Sci. 1999 Dec;14(6):648-52
references: 10642943
references: Neuropharmacology. 2007 Sep;53(3):353-61
references: 17583756
references: Food Chem Toxicol. 2005 Jan;43(1):57-63
references: 15582196
references: Comp Biochem Physiol C Toxicol Pharmacol. 2001 Sep;130(1):19-27
references: 11544140
references: Pharmacol Ther. 2007 Aug;115(2):246-70
references: 17555825
references: Biochem Biophys Res Commun. 2000 Jun 7;272(2):539-43
references: 10833448
references: Science. 1972 Jul 28;177(4046):314-22
references: 4113805
references: Singapore Med J. 2000 Jan;41(1):9-13
references: 10783673
references: Neurology. 2005 Dec 13;65(11):1764-8
references: 16221950
references: BMC Pharmacol. 2004 Jun 08;4:9
references: 15182373
references: Exp Mol Med. 2001 Jun 30;33(2):64-8
references: 11460883